Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Cash from Operations (2020 - 2022)

Atea Pharmaceuticals has reported Cash from Operations over the past 3 years, most recently at 21545000.0 for Q4 2022.

  • Quarterly results put Cash from Operations at 21545000.0 for Q4 2022, up 71.43% from a year ago — trailing twelve months through Dec 2022 was 120982000.0 (down 39.05% YoY), and the annual figure for FY2025 was 132031000.0, up 2.56%.
  • Cash from Operations for Q4 2022 was 21545000.0 at Atea Pharmaceuticals, down from 21242000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for AVIR hit a ceiling of 318521000.0 in Q4 2020 and a floor of 75423000.0 in Q4 2021.
  • Median Cash from Operations over the past 3 years was 17092500.0 (2021), compared with a mean of 7395583.33.
  • Peak annual rise in Cash from Operations hit 338.4% in 2021, while the deepest fall reached 273.49% in 2021.
  • Atea Pharmaceuticals' Cash from Operations stood at 318521000.0 in 2020, then tumbled by 123.68% to 75423000.0 in 2021, then skyrocketed by 71.43% to 21545000.0 in 2022.
  • The last three reported values for Cash from Operations were 21545000.0 (Q4 2022), 21242000.0 (Q3 2022), and 19186000.0 (Q2 2022) per Business Quant data.